In consultation: Guidance and quality standards

Skip to filters Skip to results

Showing 1 to 9 of 9

Sort by

Type: Guidance`Remove $Type: Guidance filter`
Type: NICE advice`Remove $Type: NICE advice filter`
Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`
Guidance programme: Interventional procedures guidance`Remove $Guidance programme: Interventional procedures guidance filter`
Guidance programme: Social care guidelines`Remove $Guidance programme: Social care guidelines filter`

Guidance and quality standards in consultation
Title	Consultation	Type	Consultation end date
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]	Draft guidance	Technology appraisal guidance	11 May 2026
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]	Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators	Technology appraisal guidance	1 May 2026
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]	Final draft guidance	Technology appraisal guidance	30 April 2026
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]	Draft guidance	Technology appraisal guidance	28 April 2026
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]	Draft guidance	Technology appraisal guidance	28 April 2026
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]	Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators	Technology appraisal guidance	28 April 2026
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]	Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators	Technology appraisal guidance	28 April 2026
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]	Draft guidance	Technology appraisal guidance	24 April 2026
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]	Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators	Technology appraisal guidance	20 April 2026

Results per page

10
25
50
All